Indaptus extends outside date for $24 million private placement to October 16
A Form 8-K filed September 30, 2026 reports that Indaptus and its purchasers agreed on September 29, 2026 to extend the closing deadline for a stock sale.
SEC filing
Latest
5 stories
Yesterday
Wednesday, September 9
Indaptus Therapeutics raises $24 million in private placement, revamps ATM agreement
The company sold over 20 million shares in a private placement and separately entered an amended $100 million at-the-market sales agreement with H.C. Wainwright.
SEC filing (3)
Friday, September 4
Indaptus Therapeutics board member Tim Ruan resigns effective immediately
Indaptus disclosed in an SEC filing that director Tim Ruan stepped down from its board on September 2, 2026, with no stated dispute behind the move.
SEC filing
Indaptus corrects dilution math in $100M at-the-market offering prospectus
An amendment filed September 4, 2026 fixes a clerical error in dilution figures tied to Indaptus's up-to-$100 million stock offering with H.C. Wainwright.
SEC filing (2)
Thursday, August 13
Indaptus halts Decoy20 enrollment, pivots to strategic review after Q2 2026
Indaptus Therapeutics reported no active clinical programs and a new sleep-related research collaboration as it evaluates strategic alternatives following a $12.0 million private placement.
SEC filing